Detection of Bone Metastases by ⁶⁸Ga-DOTA-SSAs and ¹⁸F-FDG PET/CT: A Two-Center Head-to-Head Study of Gastroenteropancreatic Neuroendocrine Neoplasms

Figure 2

Dual-tracer imaging in a 46-year-old woman with NET G3 (Ki-67 index 22%) accompanied by liver, lymph node, and bone metastases of unknown primary origin: (a1, a2) Maximum intensity projection of dual-tracer imaging; (b1, b2) Sternum lesion with somatostatin receptor (SSTR) expression on ⁶⁸Ga-DOTA-SSAs PET/CT but no bone metastases were detected by ¹⁸F-FDG PET/CT; (c1, c2) ¹⁸F-FDG PET/CT imaging of liver lesions showing liver metastases (LMs) with higher FDG metabolism, while ⁶⁸Ga-DOTA-SSAs PET/CT imaging showed LMs with lower SSTR expression.